Ginkgo Bioworks receives lower rating from TD Cowen

TD Cowen recently downgraded biotech company Ginkgo Bioworks. According to the source, there is uncertainty about the company's future growth.

Ginkgo Bioworks is a company that focuses on developing natural solutions in the health sector. The company uses biotechnological methods to create products.

The downgrade by TD Cowen comes because, according to analysts, there is insufficient certainty about Ginkgo Bioworks' growth. The company has already launched several innovations in the past.

It is unclear how Ginkgo Bioworks will respond to the lower rating. The company continues to focus on developing new natural products.

This report is a summary based on the mentioned source and is not medical advice. Consult a doctor or pharmacist in case of complaints.